Every earnings call for AARTIPHARM — management tone, guidance, KPIs and promise tracking, quarter by quarter.
AARTIPHARM · 5 transcripts · Healthcare · latest Q3 FY26Revenue ₹425 cr (−10% YoY); EBITDA ₹103 cr (−10% YoY); PAT ₹44 cr (−41% YoY). Q3 FY26 Revenue at ₹425 crores, down from ₹471 crores YoY.
Read full transcript & analysisStandalone Revenue ₹417 cr (+11% YoY); Standalone EBITDA ₹75 cr (−12% YoY); Standalone PAT ₹31 cr (−35% YoY). Standalone revenue grew 11% YoY to INR 417 crores.
Read full transcript & analysisStandalone EBITDA ₹95 cr (+13% YoY); Standalone PAT ₹51 cr (+9% YoY). Standalone EBITDA grew 14% YoY to ₹95 crores.
Read full transcript & analysisRevenue (Q4 FY25) ₹564 cr (+11% YoY); EBITDA (Q4 FY25) ₹146 cr (+24% YoY); EBITDA Margin (Q4 FY25) 26.0%. FY25 Revenue of ₹2,113 crores, up 14% YoY.
Read full transcript & analysisConsolidated Revenue ₹538 cr (+20% YoY); Consolidated EBITDA ₹129 cr (+34% YoY); EBITDA Margin 23.98%. Consolidated top line was ₹538 crores, a 20% increase YoY.
Read full transcript & analysis